Peter Rothschild, CEO of BioGaia, summarizes the second quarter of 2013 and answers to questions regarding the new deal with Nestlé, expectations on the the new distribution agreements in China and South Korea, what it means to be classified as an “orphan drug” by the FDA and also the regulatory progress in Brazil.

See the interview on the BioGaia YouTube-channel